Loading, Please Wait...
WOBURN, Mass., Sept. 10, 2018 (GLOBE NEWSWIRE) -- Yield10 Bioscience, Inc. (Nasdaq:YTEN), a Company developing new technologies to create step-change improvements in crop yield to enhance global food security, today announced that Meghna Malik, Ph.D., Team Leader, will be presenting later today, September 10, at the Canadian Lipid and Bioresource Conference 2018 (CLBC2018), the Canadian Section of the American Oil Chemists’ Society (CAOCS). Dr. Malik’s presentation is titled “The Yield10 Bioscience Platform: Technologies for increasing seed yield and oil content in oilseeds.” The presentation is part of the Plant Lipid Metabolism and Biotechnology program which is scheduled from 1:30 to 2:50 pm local time. The CLBC 2018 is being held Sept. 9-11 in Saskatoon, Saskatchewan, Canada.
Dr. Malik will describe the various approaches Yield10 and its wholly owned subsidiary, Metabolix Oilseeds, are taking to increase seed yield and oil content in oil seed crops. During her presentation, Dr. Malik will discuss the creation of a complex multi-gene pathway based on a synthetic carbon fixation pathway. When introduced into Camelina, the synthetic pathway produced a doubling of seed yield in greenhouse studies. While too complex to commercialize, this work provided Yield10 researchers with insights into the use of metabolic engineering to identify new yield traits in plants.
Dr. Malik will also provide an overview of Yield10’s work with C3003, a novel yield trait gene based on CCP1, a gene found in algae. The presentation will include results with C3003 based on a series of greenhouse and field tests in Camelina, canola and soybean. Dr. Malik will also describe recent preliminary results with C3004, a novel yield trait expressed in Camelina, where Yield10 has observed robust increases in seed yield and branching in growth chamber tests in Camelina. In a recent press release, Yield10 reported that Camelina plant lines containing C3004 grew vigorously, and the best lines produced increases in seed yield in a range of 26% to 65% as compared to control plants. In the presentation, Dr. Malik will also describe five novel traits based on CRISPR-Cas9 genome-editing being studied by Yield10 to drive increases in oil biosynthesis in Camelina, canola and specialty oil crops.
Learn more about the conference at the Canadian Lipid and Bioresource Conference 2018 website. A copy of Dr. Malik’s slide deck will be available on the Yield10 Bioscience investor relations website.
About Yield10 Bioscience
Yield10 Bioscience, Inc. is focused on developing new technologies to achieve step-change improvements in crop yield to enhance global food security. Yield10 has an extensive track record of innovation based around optimizing the flow of carbon in living systems. Yield10 is leveraging its technology platforms and unique knowledge base to design precise alterations to gene activity and the flow of carbon in plants to produce higher yields with lower inputs of land, water or fertilizer. Yield10 is advancing several yield traits it has developed in crops such as Camelina, canola, soybean and rice. Yield10 is headquartered in Woburn, MA and has an Oilseeds Center of Excellence in Saskatoon, Canada.
For more information about the company, please visit www.yield10bio.com.
Safe Harbor for Forward-Looking Statements
This press release contains forward-looking statements which are made pursuant to the safe harbor provisions of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. The forward-looking statements in this release do not constitute guarantees of future performance. Investors are cautioned that statements in this press release which are not strictly historical, including, without limitation, the use of the Company’s technology to successfully identify targets and develop systems for increasing crop yield, the ability of greenhouse and growth chamber studies to predict yield results in field tests, and progress by Yield10 in driving increases in oil biosynthesis and developing its products, constitute forward-looking statements. Such forward-looking statements are subject to a number of risks and uncertainties that could cause actual results to differ materially from those anticipated, including the risks and uncertainties detailed in Yield10 Bioscience's filings with the Securities and Exchange Commission. Yield10 assumes no obligation to update any forward-looking information contained in this press release or with respect to the matters described herein.
Lynne H. Brum, (617) 682-4693, LBrum@yield10bio.com
Amato and Partners, LLC
Fischtank Marketing and PR